23.09.2020 • News

OQ Chemicals Licenses Technologies to Duqm

OQ Chemicals – formerly Oxea – has agreed to license its proprietary technology for the production of ethylene and propylene derivatives to Oman’s Duqm Refinery and Petrochemicals Industries Company (DRPIC).

A joint venture between Oman Oil and Kuwait International Oil, DRPIC is planning a grassroots petrochemical complex at Duqm and has so far awarded 12 license packages to international technology providers.

Earlier this month, LyondellBasell announced it had been chosen to license its Spheripol PP and Hostalen HDPE technologies for plants at the proposed complex.

The contract with OQ Chemicals covers five plants to manufacture propanol, butyraldehyde, neopentyl glycol, 2-ethylhexanol (2-EH) and 2-EH acid. OQ Chemicals will supply a process design package and support contractors during the design and construction phases, along with providing various other services that include operational support, maintenance, training and ongoing process optimization.

OQ Chemicals chief operating officer Oliver Borgmeier said the company is applying the latest technologies at Duqm that it has developed for its own production plants in Bay City, Texas, USA, and Oberhausen, Germany.

Part of Oman Oil since 2013, Germany’s Oxea changed its name to OQ Chemicals in May this year, marking its final integration into Oman’s new petrochemicals and energy giant OQ.

 

Author: Elaine Burridge, Freelance Journalist

OQ Chemicals is to license its technology for the production of ethylene and...
OQ Chemicals is to license its technology for the production of ethylene and propylene derivatives to Oman’s Duqm Refinery and Petrochemicals Industries Company. The contract covers five plants for propanol, butyraldehyde, neopentyl glycol, 2-ethylhexanol (2-EH) and 2-EH acid. (c) OQ

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read